Unicycive Therapeutics (NASDAQ:UNCY) Coverage Initiated at Guggenheim

Guggenheim started coverage on shares of Unicycive Therapeutics (NASDAQ:UNCY - Free Report) in a research note released on Monday morning, MarketBeat Ratings reports. The firm issued a buy rating and a $6.00 target price on the stock.

Separately, HC Wainwright reissued a "buy" rating and set a $7.50 price objective on shares of Unicycive Therapeutics in a report on Friday, April 11th.

Unicycive Therapeutics Stock Performance

NASDAQ UNCY remained flat at $0.64 during mid-day trading on Monday. 228,815 shares of the company were exchanged, compared to its average volume of 1,455,506. The firm has a market cap of $76.61 million, a PE ratio of -0.66 and a beta of 2.15. The business's 50-day moving average price is $0.58 and its two-hundred day moving average price is $0.59. Unicycive Therapeutics has a 52 week low of $0.20 and a 52 week high of $1.29.

Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) last released its quarterly earnings data on Thursday, March 27th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.13). On average, research analysts expect that Unicycive Therapeutics will post -0.23 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Northern Trust Corp increased its position in shares of Unicycive Therapeutics by 142.4% during the 4th quarter. Northern Trust Corp now owns 58,181 shares of the company's stock valued at $46,000 after purchasing an additional 34,183 shares during the last quarter. Virtu Financial LLC increased its holdings in Unicycive Therapeutics by 566.8% during the third quarter. Virtu Financial LLC now owns 73,975 shares of the company's stock valued at $30,000 after buying an additional 62,881 shares during the last quarter. XTX Topco Ltd bought a new position in Unicycive Therapeutics in the third quarter worth approximately $29,000. Geode Capital Management LLC raised its position in Unicycive Therapeutics by 30.3% in the fourth quarter. Geode Capital Management LLC now owns 524,487 shares of the company's stock worth $417,000 after acquiring an additional 122,089 shares during the period. Finally, Acuta Capital Partners LLC boosted its stake in shares of Unicycive Therapeutics by 16.4% during the 4th quarter. Acuta Capital Partners LLC now owns 2,303,000 shares of the company's stock worth $1,829,000 after acquiring an additional 323,801 shares during the last quarter. Institutional investors own 40.42% of the company's stock.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.